Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana 47907, United States.
Merck & Co., Inc. 2000, Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Mol Pharm. 2021 May 3;18(5):2066-2081. doi: 10.1021/acs.molpharmaceut.1c00055. Epub 2021 Mar 30.
Dissolution of amorphous solid dispersions (ASD) can lead to the formation of amorphous drug-rich nano species (nanodroplets) via liquid-liquid phase separation or glass-liquid phase separation when the drug concentration exceeds the amorphous solubility. These nanodroplets have been shown to be beneficial for ASD performance both and . Thus, understanding the generation and stability of nanodroplets from ASD formulations is important. In this study, the impacts of polymer selection and active pharmaceutical ingredient (API) physicochemical properties (wet glass transition temperature () and log ) on nanodroplet release were studied. Six APIs with different physicochemical properties were formulated as ASDs with two polymers, polyvinylpyrrolidone/vinyl acetate (PVPVA) and hydroxypropyl methylcellulose acetate succinate (HPMCAS). Their release performance was evaluated using both powder and surface normalized dissolution of compacts. In general, HPMCAS-based dispersions resulted in higher drug release compared to PVPVA-based dispersions. The two polymers also exhibited different trends in nanodroplet formation as a function of drug loading (DL). PVPVA ASDs exhibited a "falling-off-the-cliff" effect, with a dramatic decline in release performance with a small increase in drug loading, while HPMCAS ASDs exhibited a negative "slope" in the release rate as a function of drug loading. For both polymers, low compounds achieved higher levels of nanodroplet formation compared to high compounds. The nanodroplets generated from ASD dissolution were also monitored with dynamic light scattering, and HPMCAS was found to be more effective at stabilizing nanodroplets against size increase. Insights from this study may be used to guide formulation design and selection of excipients based on API physicochemical properties.
无定形固体分散体(ASD)的溶解会导致药物浓度超过无定形溶解度时通过液-液相分离或玻璃-液相分离形成无定形药物富纳米级物种(纳米液滴)。已经证明,这些纳米液滴有利于 ASD 的性能和 。因此,了解 ASD 制剂中纳米液滴的生成和稳定性非常重要。在这项研究中,研究了聚合物选择和活性药物成分(API)物理化学性质(湿玻璃化转变温度(Tg,w)和 log )对纳米液滴释放的影响。选择了具有不同物理化学性质的六种 API 与两种聚合物(聚乙烯吡咯烷酮/醋酸乙烯酯(PVPVA)和羟丙基甲基纤维素醋酸琥珀酸酯(HPMCAS))制成 ASD。使用粉末和表面归一化压缩物溶解来评估它们的释放性能。一般来说,基于 HPMCAS 的分散体比基于 PVPVA 的分散体导致更高的药物释放。两种聚合物还表现出随着药物负载(DL)变化而形成纳米液滴的不同趋势。PVPVA ASD 表现出“悬崖坠落”效应,药物负载略有增加,释放性能急剧下降,而 HPMCAS ASD 则表现出随着药物负载增加释放速率呈负“斜率”的趋势。对于两种聚合物,低 Tg,w 化合物比高 Tg,w 化合物形成更高水平的纳米液滴。还使用动态光散射监测 ASD 溶解产生的纳米液滴,发现 HPMCAS 更有效地稳定纳米液滴防止粒径增大。这项研究的结果可用于根据 API 物理化学性质指导制剂设计和赋形剂选择。